- Lupin inaugurated its new 18,000 sq. ft. corporate office in Bridgewater, New Jersey, expanding its U.S. presence.
- The new facility will host corporate, R&D, and commercial operations, supporting the company’s continued growth in the region.
Lupin Limited, a global pharmaceutical company, has inaugurated its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The move strengthens Lupin’s presence in the state, where it already operates manufacturing and research facilities in Somerset.
The ribbon-cutting ceremony was attended by New Jersey Governor Phil Murphy and Somerset County Commissioner Deputy Director Melonie Marano, alongside Lupin executives including CEO Vinita Gupta, President of U.S. Generics Spiro Gavaris, and Chief Technical Operations Officer Christoph Funke.
The 18,000-square-foot office will accommodate a range of corporate functions, including commercial, human resources, finance, legal, marketing, business development, and R&D. Lupin first established its presence in New Jersey in 2016 following the acquisition of a manufacturing facility in Somerset.
Governor Phil Murphy said the expansion reflects New Jersey’s strength in pharmaceuticals and its contribution to economic growth and job creation.
“Our operations in the state, including corporate offices, manufacturing and research facilities, have been an important part of our U.S. growth and expansion. This foundation enables us to drive innovation and provide access to affordable, high-quality medications nationwide.”
Vinita Gupta, CEO of Lupin
Lupin now employs over 300 people in New Jersey, with plans to expand further. The company also recently announced a new manufacturing facility in Coral Springs, Florida, to produce respiratory therapies for the U.S. market, reinforcing its long-term commitment to innovation and accessibility in healthcare.
